Rankings / Hormones & Endocrine
Clomiphene citrate
Hormones & Endocrine · SERM (HPG restart)
Tier C+
Bottom line
Read Off Label grades Clomiphene citrate as C+ (5.5/10) based on moderate evidence, med benefit magnitude, and a med-risk safety profile.
Clomiphene has been studied in men where raising LH/FSH and preserving spermatogenesis are outcomes, in contrast with exogenous testosterone's suppressive HPG-axis effects.
Studied, labeled, or reported-use context: 25-50 mg every other day or daily in male off-label protocols; fertility induction protocols vary — Rx; not individualized guidance.
Citation correction in progress
2 PubMed links were found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Clomiphene has been studied in men where raising LH/FSH and preserving spermatogenesis are outcomes, in contrast with exogenous testosterone's suppressive HPG-axis effects. DailyMed labeling lists visual symptoms including blurred vision and scotomata and calls for discontinuation and evaluation if they occur. Hohl 2025 systematic review/meta-analysis found SERM therapy increased total testosterone by about 274 ng/dL vs placebo and raised LH/FSH. The mixed-isomer drug has more clinical history than enclomiphene but also more estrogen-receptor activity outside the hypothalamus. A second 2026 SR/MA (11 studies, n=1,512; Eur J Clin Pharmacol) found no significant difference in serum testosterone between clomiphene and testosterone gel, but TRT produced better libido scores (ADAM 1-5, p=0.009) -- shows a fertility-preserving treatment context with different sexual-function outcomes from TRT.
Mechanism
Mixed SERM containing enclomiphene (trans isomer) plus zuclomiphene (cis isomer); blocks hypothalamic estrogen feedback, increasing GnRH → LH/FSH → endogenous testosterone and spermatogenesis
Studied, labeled, or reported dose & route
25-50 mg every other day or daily in male off-label protocols; fertility induction protocols vary
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Clomiphene citrate's effects?
- Read Off Label rates the evidence for Clomiphene citrate as Moderate and the benefit magnitude as med, producing an overall grade of C+ (5.5/10). Clomiphene has been studied in men where raising LH/FSH and preserving spermatogenesis are outcomes, in contrast with exogenous testosterone's suppressive HPG-axis effects.
- What safety findings are reported for Clomiphene citrate?
- Clomiphene citrate has a med risk profile in the database. Med (visual symptoms labeled; mood changes; hot flashes; gynecomastia; rare VTE; male use is off-label) Legal status: Rx (FDA-approved for female ovulatory infertility; male hypogonadism use off-label).
- What doses or routes are reported for Clomiphene citrate?
- 25-50 mg every other day or daily in male off-label protocols; fertility induction protocols vary This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Clomiphene citrate work?
- Mixed SERM containing enclomiphene (trans isomer) plus zuclomiphene (cis isomer); blocks hypothalamic estrogen feedback, increasing GnRH → LH/FSH → endogenous testosterone and spermatogenesis
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.